Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - INNOVUS PHARMACEUTICALS, INC. | innv8k_nov142017.htm |
Exhibit
99.1
Innovus Pharma Launches FlutiCare™ OTC Nasal Spray Allergy
Relief in the U.S.
Product Currently Expected to
Generate $10-$15m in Additional Revenues Annually
San
Diego, CA, November 14, 2017 – Innovus Pharmaceuticals, Inc.
("Innovus Pharma" or the “Company”) (OTCQB Venture
Market: INNV), an emerging commercial-stage pharmaceutical company
that delivers safe, innovative and effective over-the-counter
(“OTC”) medicine and consumer care products to improve
men’s and women's health and respiratory diseases, today
announced that it has officially launched FlutiCare™ OTC in the U.S. FlutiCare™ contains
the most prescribed nasal steroid active pharmaceutical ingredient
(“API”) and form for nasal allergy relief over the last
7 years. The Company is launching FlutiCare™ to over 10,000
independent pharmacies, direct and through Amerisource Bergen and
McKesson, via its Beyond Human® print media platform and
through its extensive online channels and distributors including
its own websites and Amazon and Walmart online stores. As a second
phase of its launch, Innovus Pharma will launch
FlutiCare™ to large retail
stores.
FlutiCare™ will be available OTC with the same prescription
strength and same delivery method as Flonase®* and
ClariSpray®*. The Company currently believes that
FlutiCare™ will be the most affordable fluticasone propionate
nasal spray on the market and is now available in one dose, 30 Day
(120 Sprays) treatment and is the only one providing a monthly
autoship plan.
“We are very excited to launch FlutiCare™ OTC and provide all patients with
allergy relief,” stated Dr. Bassam Damaj, President and Chief
Executive Officer of Innovus Pharma. “FlutiCare™ traces
its roots as the most prescribed Rx 24-hour nasal allergy spray API
and form in the U.S. over the past 7 years by a factor of over 10
to 1,” he continued.
FlutiCare™ was approved by the U.S. Food and Drug
Administration (“FDA”) for OTC sale through Innova
Pharma's partner’s approved abbreviated new drug application
(“ANDA”) No. 207957. FlutiCare™ allergy relief joins the growing
Innovus Pharma product family, offering a burgeoning portfolio of
non-prescription medicine and consumer care
products.
FlutiCare™ becomes the Company’s second available
allergy relief product along with AllerVarx™, a patented
clinical dietary supplement formulated to provide relief during the
allergy season, already on the market.
In addition, the Company, pending FDA’s guidance, plans to
move forward with the submission of a fluticasone kit for nasal
allergy containing FlutiCare™ and our upcoming saline nasal
spray NasaVa™.
About FlutiCare™
FlutiCare™ is a nasal spray, which provides 50 micrograms of
fluticasone propionate (“USP”) per spray, a nasal
corticosteroid that provides 24-hour temporary relief of seasonal
and perennial nasal allergy symptoms. FlutiCare™ can be used
to relieve both indoor and outdoor nasal allergy symptoms caused by
pollen, dust, animal dander, and other indoor and outdoor
allergens. Nasal allergy symptoms include, nasal congestion, runny
nose, sneezing, itchy nose, etc.
FlutiCare™ contains the nasal steroid API that is physician
recommended and consumer preferred
●
#1
form used by patients;
●
#1
nasal steroid active prescribed by physicians;
●
Familiar
to patients, comfort of a known & trusted
medicine;
●
Engrained
in patients’ allergy management; and
●
Effective
and safe.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging
OTC consumer goods and specialty pharmaceutical company engaged in
the commercialization, licensing and development of safe and
effective non-prescription medicine and consumer care products to
improve men’s and women’s health and vitality and
respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health
solutions through its (a) OTC medicines and consumer and health
products, which we market directly, (b) commercial partners to
primary care physicians, urologists, gynecologists and
therapists, and (c) directly to consumers through our on-line
channels, retailers and wholesalers. The Company is dedicated to
being a leader in developing and marketing new OTC and branded
Abbreviated New Drug Application (“ANDA”) products,
men’s and women’s health supplements, related
diagnostics and medical devices. The Company is actively pursuing
opportunities where existing prescription drugs have recently, or
are expected to, change from prescription (or Rx) to OTC, as well
as related products.
For
more information, go to www.innovuspharma.com;
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.prostagorx.com;
www.fluticare.com;
www.allervarx.com;
and www.apeaz.com.
Innovus Pharma's Forward-Looking Safe Harbor:
Statements
under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this
release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may
individually or mutually impact the matters herein described for a
variety of reasons that are outside the control of the Company,
including, but not limited to, projected revenues from the
FlutiCare™ product in the
United States if approved in that country, estimated market for its
products, and statements about achieving its other development,
growth, commercialization, financial and staffing objectives.
Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ
materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the
Company's most recent filing on Form
S-1, annual report on Form 10-K, subsequent quarterly reports filed
on Form 10-Q and other filings made with the SEC. Copies of these
reports are available from the SEC's website or without charge from
the Company.
*Flonase® is a registered trademark of GSK and
ClariSpray® is a registered trademark of Bayer.
###
Contact:
James
S. Painter III
Emerging
Markets Consulting, LLC
Tel:
407 340 0226
jamespainter@emergingmarketsllc.com
or
Matt
Anthes
MyEPK
Media
424-256-9375
matt@myEPKmedia.com